KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLand & ImprovementsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bristol Myers Squibb (BMY) Non-Current Deffered Revenue (2016 - 2019)

Historic Non-Current Deffered Revenue for Bristol Myers Squibb (BMY) over the last 11 years, with Q1 2019 value amounting to $448.0 million.

  • Bristol Myers Squibb's Non-Current Deffered Revenue rose 22.37% to $448.0 million in Q1 2019 from the same period last year, while for Mar 2019 it was $448.0 million, marking a year-over-year increase of 22.37%. This contributed to the annual value of $468.0 million for FY2018, which is 308.37% up from last year.
  • Latest data reveals that Bristol Myers Squibb reported Non-Current Deffered Revenue of $448.0 million as of Q1 2019, which was up 22.37% from $468.0 million recorded in Q4 2018.
  • In the past 5 years, Bristol Myers Squibb's Non-Current Deffered Revenue ranged from a high of $697.0 million in Q1 2015 and a low of $447.0 million during Q1 2018
  • For the 5-year period, Bristol Myers Squibb's Non-Current Deffered Revenue averaged around $542.5 million, with its median value being $528.0 million (2017).
  • Its Non-Current Deffered Revenue has fluctuated over the past 5 years, first plummeted by 3598.85% in 2015, then skyrocketed by 308.37% in 2018.
  • Over the past 5 years, Bristol Myers Squibb's Non-Current Deffered Revenue (Quarter) stood at $586.0 million in 2015, then dropped by 6.66% to $547.0 million in 2016, then dropped by 17.0% to $454.0 million in 2017, then increased by 3.08% to $468.0 million in 2018, then decreased by 4.27% to $448.0 million in 2019.
  • Its Non-Current Deffered Revenue was $448.0 million in Q1 2019, compared to $468.0 million in Q4 2018 and $486.0 million in Q3 2018.